The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2020
Filed:
Oct. 01, 2018
Applicants:
The University of British Columbia, Vancouver, CA;
Promis Neurosciences, Inc, Toronto, CA;
Inventor:
Neil R. Cashman, Vancouver, CA;
Assignee:
The University of British Columbia, Vancouver, CA;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); C07K 16/00 (2006.01); C12P 21/08 (2006.01); G01N 33/53 (2006.01); A61K 38/07 (2006.01); A61K 38/12 (2006.01); A61K 39/385 (2006.01); A61K 47/64 (2017.01); C07K 14/47 (2006.01); C07K 5/117 (2006.01); C07K 7/06 (2006.01); C07K 7/64 (2006.01); C12N 5/16 (2006.01); G01N 33/68 (2006.01); A61P 25/28 (2006.01); C07K 16/18 (2006.01); C07K 5/083 (2006.01); C07K 5/087 (2006.01); C07K 5/09 (2006.01); C07K 5/093 (2006.01); C07K 5/097 (2006.01); C07K 5/113 (2006.01); A61K 51/08 (2006.01); A61K 49/18 (2006.01); A61K 45/00 (2006.01); A61K 38/00 (2006.01); A61K 38/05 (2006.01); A61K 51/10 (2006.01); A61K 47/68 (2017.01); A61K 38/08 (2019.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/69 (2017.01); A61L 31/10 (2006.01); A61L 27/34 (2006.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01); A61L 29/08 (2006.01); A61L 27/22 (2006.01); G01N 33/50 (2006.01); C07K 5/103 (2006.01); C07K 14/435 (2006.01); C12N 5/10 (2006.01); C07K 7/08 (2006.01);
U.S. Cl.
CPC ...
A61K 38/07 (2013.01); A61K 38/12 (2013.01); A61K 39/385 (2013.01); A61K 47/643 (2017.08); A61K 47/646 (2017.08); A61P 25/28 (2018.01); C07K 5/081 (2013.01); C07K 5/0808 (2013.01); C07K 5/0812 (2013.01); C07K 5/0815 (2013.01); C07K 5/0819 (2013.01); C07K 5/0821 (2013.01); C07K 5/1021 (2013.01); C07K 5/1024 (2013.01); C07K 7/06 (2013.01); C07K 7/64 (2013.01); C07K 14/4711 (2013.01); C07K 16/18 (2013.01); C12N 5/16 (2013.01); G01N 33/6896 (2013.01); A61K 38/00 (2013.01); A61K 38/05 (2013.01); A61K 38/08 (2013.01); A61K 39/00 (2013.01); A61K 39/39 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 45/05 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6921 (2017.08); A61K 49/1818 (2013.01); A61K 49/1866 (2013.01); A61K 51/088 (2013.01); A61K 51/10 (2013.01); A61K 51/1018 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/6081 (2013.01); A61K 2300/00 (2013.01); A61L 27/227 (2013.01); A61L 27/34 (2013.01); A61L 29/085 (2013.01); A61L 29/16 (2013.01); A61L 31/10 (2013.01); A61L 31/16 (2013.01); C07K 5/101 (2013.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C12N 5/10 (2013.01); G01N 33/5058 (2013.01); G01N 2333/4709 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/387 (2013.01);
Abstract
The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.